within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AX04_DermatanSulfate;

model DermatanSulfate
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 5.25e-06,
    adminDuration = 600,
    adminMass = 1000 / 1000000,
    adminCount = 1,
    Vd = 5.9999999999999995e-05,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>DermatanSulfate</td></tr><tr><td>ATC code:</td><td>B01AX04</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>1000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.06</td><td>L</td></tr>
    <tr><td>clearance:</td><td>4.5</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Dermatan sulfate is a glycosaminoglycan anticoagulant drug used in the prophylaxis and treatment of thromboembolic disorders. It enhances inhibition of thrombin and other coagulation factors. Dermatan sulfate is not currently approved by the FDA but has been used in some countries in the past. Its use is limited today, mainly replaced by heparins and direct oral anticoagulants.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for intravenous administration in adult patients, due to absence of published human PK data.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.B.B01AX04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end DermatanSulfate;
